The news releases are issued by FUJIFILM Corporation in Japan.
Fujifilm makes no representation that products on these news releases are commercially available in all countries and regions.
Please note that contents in this website are current as of the date of the press announcement and may be subject to change without prior notice. Information in each release, including the product availability, specification, prices, contacts, are those at the time of publication.
- Nov 5, 2024
- FUJIFILM Diosynth Biotechnologies Launches First Phase of Global CDMO Ecosystem Expansion
- Apr 12, 2024
- Fujifilm to Invest Additional $1.2 Billion to Expand its Large-Scale Cell Culture CDMO Business in North Carolina
- Feb 29, 2024
- FUJIFILM Diosynth Biotechnologies Announces Renewable Energy PPA with Better Energy for Denmark Manufacturing Site
- Dec 5, 2023
- Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities
- Nov 8, 2023
- FUJIFILM Diosynth Biotechnologies Announces First Tenant for New Manufacturing Facility
- Jun 6, 2023
- Fujifilm to Enhance Commercial Presence in Asia for Biologics and Advanced Therapies Contract Services
- Mar 31, 2023
- Transfer of FUJIFILM Healthcare Systems’ electronic medical record and medical-receipt systems related business to PHC Holdings’ subsidiary
- Dec 20, 2022
- Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to acquire the company’s Digital Pathology Business
- Dec 14, 2022
- Fujifilm Invests in PhenoVista Biosciences from its Life Sciences Corporate Venture Capital Fund
- Oct 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan
- Jun 30, 2022
- Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services
- Apr 5, 2022
- Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Mar 22, 2022
- Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product